Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Carolyn Bertozzi and Degrading Drugs for Problematic Proteins
Deploying AI Platforms to Identify Sepsis
Discovery, Translation, and the State of Bio Today
Engineering an Epigenome Editor
Evolving Embodied Intelligence
Building Digital Health's Github
The Genetic Testing (R)Evolution
The Problem with Urgent Care
Viral Genomes from A to Z
World’s largest supercomputer v. biology’s toughest problems
The Trials of Clinical Trials
The New Science of Cell Shape
Journal Club: Sleeping Under the Star-Shaped Cells
The Power of Patient-Centric Healthcare
Journal Club: Hunting the Eagle Killer
Journal Club: Sourcing the Secrets of Climate Adaptation
Evolution: Animals, Aliens, and Ourselves
Journal Club: Bioengineering Birth... Again!
Solving Medical Mysteries in the World of Rare Disease
Journal Club: Taming the Taste for Blood
Create your
podcast in
minutes
It is Free